Fundraising FoxHarpoon Therapeutics
South San Francisco, US · Delaware corporation · 8 known investors
Find your way into Harpoon Therapeutics
Sign up to see every warm intro you have to Harpoon Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Harpoon Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
A research-intensive biopharmaceutical company that develops medicines and vaccines. It serves patients and provides health-related information across global communities.
Founders & leadership
LN
Luke Nathaniel WalkerExecutive
JE
Julie EastlandChief Executive Officer2021–2024She brings over 25 years of experience in life sciences leadership, including roles overseeing clinical-stage and commercial operations, and has held CFO positions and board appointments at multiple public and private biopharma companies.
Board
RH
Ronald HuntBoard director
MC
Mark ChinBoard director
AC
Alan ColowickBoard director
JD
Jonathan DrachmanBoard director
JV
Joanne VineyBoard director
JB
Joseph BailesBoard director
AR
Andrew RobbinsBoard director
SM
Scott MyersBoard director
LP
Lauren P. SilvernailMember Board of Directors and Chair, Audit Committee2022–2024Executive Officer at Evolus
Investors · 8
K2 HealthVentureslisted by K2 HealthVenturesBoston
How we know: K2 HealthVentures's portfolio page · Not right? Tell us
Ridgeback Capitallisted by Ridgeback CapitalNew York
How we know: Ridgeback Capital's portfolio page · Not right? Tell us
Arix BiosciencereportedLondon
How we know: funding news · Not right? Tell us
Lilly Asia VenturesreportedHong Kong
How we know: funding news · Not right? Tell us
MPM BioImpactreportedBoston · $1M – $15Mvia Luke Evnin · board
How we know: a partner's Signal profile · board seat on SEC Form D · funding news · Not right? Tell us
New Leaf Venture PartnersreportedNew York
How we know: funding news · Not right? Tell us
OrbiMedreportedNew York · $1M – $75M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$220.3M disclosed across 4 rounds · 2017–2023
▶$100.2MraisedOct 2023 · 18 investors · BiotechnologyRule 506(b)
▶$100.2MraisedOct 2023 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew RobbinsDirector
- Julie EastlandExecutive Officer, Director
- Luke WalkerExecutive Officer
- Mark ChinDirector
- Scott MyersDirector
- Jonathan DrachmanDirector
- Ronald HuntDirector
- Joseph BailesDirector
- Lauren SilvernailDirector
- Offering amount
- $100.2M
- Amount sold
- $100.2M
- Sales commissions
- $6.4M
- Placement agents
- Cowen and Company, LLC, H.C. Wainwright & Co., LLC, Canaccord Genuity LLC
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedApr 2023 · 6 investors · BiotechnologyRule 506(b)
▶$25MraisedApr 2023 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan DrachmanDirector
- Joanne VineyDirector
- Joseph BailesDirector
- Ronald HuntDirector
- Andrew RobbinsDirector
- Mark ChinDirector
- Luke Nathaniel WalkerExecutive Officer
- Julie EastlandExecutive Officer, Director
- Scott MyersDirector
- Lauren P. SilvernailDirector
- Alan ColowickDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$70MraisedNov 2018 · 17 investors · BiotechnologyRule 506(b)
▶$70MraisedNov 2018 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan DrachmanDirector
- Natalie R. SacksExecutive Officer
- Julie EastlandDirector
- Patrick BaeuerleDirector
- Mark ChinDirector
- Holger WescheExecutive Officer
- Gerald McMahonExecutive Officer, Director
- Scott MyersDirector
- Ron HuntDirector
- Georgia L. ErbezExecutive Officer
- Luke EvninDirector
- Offering amount
- $70M
- Amount sold
- $70M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$25.2MraisedJun 2017 · 7 investors · BiotechnologyRule 506(b)
▶$25.2MraisedJun 2017 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ron HuntDirector
- Mark ChinDirector
- Patrick BaeuerleDirector
- Gerald McMahonExecutive Officer, Director
- Luke EvninDirector
- Pablo CagnoniDirector
- William E. PichtExecutive Officer
- Dan HicklinDirector
- Offering amount
- $45.2M
- Amount sold
- $25.2M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Harpoon Therapeutics do?
- A research-intensive biopharmaceutical company that develops medicines and vaccines. It serves patients and provides health-related information across global communities.
- Who are Harpoon Therapeutics's investors?
- Harpoon Therapeutics's investors include K2 HealthVentures, Ridgeback Capital, Taiho Ventures, LLC, Arix Bioscience, Lilly Asia Ventures, MPM BioImpact, New Leaf Venture Partners, OrbiMed.
- How much funding has Harpoon Therapeutics raised?
- Harpoon Therapeutics has disclosed $220.3M raised across 4 rounds.
- Where is Harpoon Therapeutics headquartered?
- Harpoon Therapeutics is headquartered in South San Francisco, US.